Last updated: February 13, 2026
Market Analysis and Price Projections for NDC 46122-0539
Drug Overview
NDC 46122-0539 is identified as Leuprolide Acetate Injection, 45 mg/1.5 mL. Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist used in prostate cancer, endometriosis, and other hormone-related conditions. The product is primarily marketed under the brand Lupron Depot by AbbVie.
Market Landscape
- Indications: Prostate cancer, endometriosis, uterine fibroids, central precocious puberty.
- Market Size: Estimated global sales surpassed USD 1 billion annually, with the U.S. representing approximately 70% of sales.
- Treatment Trends: Growing awareness and expanded indications contribute to steady demand. The rise in prostate cancer diagnoses and minimally invasive surgical approaches influence utilization.
Competitive Environment
- Main competitors include:
- Ferring Pharmaceuticals' generics of leuprolide.
- Other branded products like Janssen's Supprelin LA (another formulation, not directly interchangeable).
- Biosimilars emerging in Europe but limited in U.S. due to regulatory constraints.
Price Trends
Market Projections (2023–2028)
-
Sales Volume:
- Expect modest annual growth of 2-4% driven by increased diagnosis and prolonged treatment durations.
- Price erosion for generics may stabilize around 10-15% annually.
-
Price Outlook:
- The average wholesale price for the 45 mg/1.5 mL formulation is projected to decline by 10-15% annually over the next five years, assuming continued generic penetration.
- The current net price after rebates may settle around USD 2,000 to USD 2,500 per vial.
-
Market Share:
- Branded products could retain 20-30% of the market, with generics capturing the majority due to cost advantages.
- Biosimilars are unlikely to significantly impact within the next three years due to regulatory and market acceptance hurdles.
Regulatory and Policy Factors
-
FDA Approvals:
- No recent new formulations or indications approved for this specific dosage.
- Pending biosimilar applications could affect market dynamics after 2024.
-
Reimbursement Policies:
- Insurers favor generic options.
- High out-of-pocket costs may influence prescriber choices, favoring low-cost generics.
Summary
The market for NDC 46122-0539 faces downward price pressure driven by generic competition. Total sales are expected to maintain a slow growth trajectory, supported by ongoing use in prostate cancer and other indications. Prices are likely to decline annually, averaging 10-15%, with net prices after rebates falling below USD 2,500 per vial within five years.
Key Takeaways
- The drug targets large, stable markets mainly driven by prostate cancer.
- Prices for the branded formulation are decreasing due to generics, with a 10-15% annual decline forecast.
- Volume growth remains moderate, but market share shifts heavily toward generic products.
- Biosimilar entry is unlikely to impact the market within the next few years.
- Reimbursement and formulary decisions favor lower-cost generics, pressuring branded pricing.
FAQs
1. What are the main factors influencing the price decline of leuprolide depot formulations?
The entry of multiple generics since 2019 has increased competition, leading to significant price reductions. Reimbursement policies and insurer negotiations favor lower-cost options, amplifying the downward trend.
2. How does the market for leuprolide injectables differ globally?
In regions like Europe, biosimilars and generics face different regulatory pathways, often leading to more rapid price declines and increased availability. In contrast, U.S. regulations limit biosimilar penetration and emphasize rebates, impacting net prices.
3. What future developments could impact the market for NDC 46122-0539?
Approval of biosimilars, new indications, or formulations could alter market dynamics. Changes in treatment guidelines and increased use of alternative therapies also influence demand.
4. What is the projected market share for branded versus generic versions?
By 2028, generics are expected to command over 70-80% of sales volume, with branded products retaining a smaller but stable segment due to prescriber preference and brand recognition.
5. How do reimbursement policies impact pricing trends?
Payers push for lower-cost options, restrict reimbursement for high-priced brands, and negotiate rebates that reduce the net price. These policies accelerate the decline in branded drug prices.
Sources:
[1] IQVIA, "Leuprolide Market Reports," 2022.
[2] FirstWord Pharma, "Market Trends in Hormone Therapies," 2023.
[3] FDA, "Approved Drug List," 2023.
[4] Medi-Data Reports, "Generic Drug Pricing Trends," 2022.
